Susceptibility to cardiovascular disease and diabetes is associated with the metabolic abnormalities of obesity, insulin resistance, dyslipidemia and hypertension (1-3). A key enzyme that has been implicated in these metabolic abnormalities is stearoyl-CoA desaturase (SCD), which introduces a cis-double bond in the ∆-9 position in its substrates, thereby converting palmitic (16:0) and stearic acid (18:0), to palmitoleic (16:1n9) and oleic acid (18:1n9), respectively (4, 5). These nutritionally and physiologically important monounsaturated fatty acids (MUFA) are the major fatty acids found in triglycerides (TG) and cholesteryl esters (CE) (6).
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Susceptibility to cardiovascular disease and diabetes is associated with the metabolic abnormalities of obesity, insulin resistance, dyslipidemia and hypertension (1) (2) (3) . A key enzyme that has been implicated in these metabolic abnormalities is stearoyl-CoA desaturase (SCD), which introduces a cis-double bond in the ∆-9 position in its substrates, thereby converting palmitic (16:0) and stearic acid (18:0) , to palmitoleic (16:1n9) and oleic acid (18:1n9), respectively (4, 5) . These nutritionally and physiologically important monounsaturated fatty acids (MUFA) are the major fatty acids found in triglycerides (TG) and cholesteryl esters (CE) (6) .
A number of mammalian SCD genes have been reported, including a human SCD on 10q24 (7) and a cluster of four genes on mouse chromosome 19 (Scd1 (8) , Scd2 (9), Scd3 (10) , and Scd4 (11)). These appear to have arisen from local duplications after divergence of the primate and rodent genomes. An additional SCD gene, SCD5, which pre-dates separation of the primate and rodent lineages, has been identified recently and is expressed in the brain and pancreas (12) (13) (14) . The most prominent site of expression for human SCD is in adipose tissue (14) , with lower expression in liver and brain (7) . Like other lipogenic genes, mammalian SCD genes are highly regulated. Human SCD is repressed in cultured cells by polyunsaturated fatty acids and cholesterol via sterol regulatory element-binding protein-1 (SREBP-1) (15) . Furthermore, SCD mRNA is elevated in skeletal muscle of obese humans (16) , and several but not all (17) observational studies in humans have shown an association between increased indices of SCD activity and components of the metabolic syndrome, including insulin resistance (18) (19) (20) (21) , obesity (16, (22) (23) (24) , and hypertension (25). The expression of mouse Scd1 in adipose tissue and liver (8, 10) and its regulation by the lipogenic transcription factors SREBP-1 and LXR (26) defines it as the most relevant murine ortholog for studying the metabolic function of SCD activity in humans.
by guest, on September 21, 2017 www.jlr.org
Downloaded from
Seven Scd1 mutant alleles have now been described in mice, including four spontaneous mutations, BALB/c-Scd1 ab (27), ABJ/Le-Scd1 ab-J (28), DBA/1LacJ-Scd1 ab-2J /J (29), and Kunming-Scd1 Xyk (30) , one chemically-induced mutation, C57BL6/J-Scd1 flk (31) , and two targeted mutations, 129S-Scd1 tm1Ntam (32) and B6129S1F2-Scd1 tm1Wst (33) . The asebia series of alleles (ab, ab-J, and ab-2J) has been studied the most extensively. Homozygosity for each is associated with atrophic sebaceous glands, alopecia, and scaly skin, phenotypes which are also observed in mice carrying the targeted disruption of the gene (32) .
SCD1-deficient mice have been observed to exhibit reduced plasma TG, increased insulin sensitivity, an increased metabolic rate, and resistance to diet-induced obesity (34, 35) . However, the impact of SCD1 deficient on hyperlipidemic mice fed a western diet is unknown.
A recent study using homozygous 129S-Scd1 tm1Ntam mice fed a chow diet has shown that SCD1 can influence the plasma lipid response to a synthetic LXR agonist (26), T0901317, which increases cholesterol efflux in hyperlipidemic mice (36, 37). However, LXR activation exacerbates hypertriglyceridemia (HTG) in hyperlipidemic mice (36, 37), and the role of SCD1 in regulating the severe LXR-induced HTG observed in hyperlipidemic mice has not yet been determined. The LDLR-deficient hyperlipidemic mouse mimics human FH and has now been used in numerous studies (48) as a model for the disrupted lipoprotein regulation and metabolic function that leads to diabetes and atherosclerosis. Unlike the most commonly used hyperlipidemic model, apoE-deficient mice (49), LDLR-deficient mice develop dietinduced diabetes and obesity when fed a western diet and also develop a lipoprotein phenotype similar to that seen in FH (48, (50) (51) (52) (53) .
Earlier studies on the beneficial metabolic effects of SCD1 deficiency have been confined to normolipidemic mice (6, 26, 34, (54) (55) (56) (57) (58) , and the influence on metabolic parameters in hyperlipidemic mice is unknown. Our results reveal that SCD1 deficiency reduces hepatic and plasma TG, inhibits diet-induced weight gain and insulin resistance, and reduces the hypertriglyceridemic effect of an LXR agonist in hyperlipidemic LDLRdeficient mice. 29.1 g, p = 0.51), but they gained less weight after feeding a western diet, (Fig. 1a) , despite tending to consume more food than controls (1.5g/day vs. 1.1g/day; p = 0.11, n = 4). mice also gained less weight than controls after feeding a western diet (Fig. 1b) (Fig. 1c) .
Results

SCD1 deficiency reduces weight gain and adiposity in
To evaluate weight gain in terms of adiposity, fat mass and lean mass were determined using magnetic resonance (MR) relaxometry, a recently validated noninvasive method for the precise assessment of body composition (61) (Fig. 2a-c) . Lean body mass was not different between SCD1-deficient mice and controls (Fig. 2b) . However, SCD1-deficient mice had a significant 50% reduction in total fat mass compared to controls (males, p = 0.0006; females, p = 0.0043). Representative images in Fig. 2c show a decrease in both visceral and subcutaneous lipid in SCD1-deficient mice. (Fig. 3a, b) , and hepatic TG levels were 5-fold higher in control Scd1 (Fig. 3c) . Fig. 4b ), but this trend was not observed in females. HDL cholesterol was not significantly altered in SCD1-deficient mice, while non-HDL cholesterol paralleled the reduction observed in plasma TC (Fig.   4c,d ). FPLC analysis confirmed the decrease in VLDL-TG in SCD1-deficient mice with a small increase noted in VLDL cholesterol (Fig. 4e-f ). Acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) are the two enzymes required for fatty acid synthesis (62, 63) . Thus, we hypothesized that the reduced fatty 
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Ldlr-/-mice. The association between obesity, HTG, and diabetes is well documented (65, 66) . To further investigate the effects of SCD1 on these parameters, the response to glucose challenge was assessed.
Male gender is a predisposing diabetes susceptibility factor in most mouse strains weeks on a western diet ( (Fig. 7f ). These data indicate that the improved glucose tolerance that was observed in mice lacking SCD1 is attributable in part to increased insulin sensitivity.
SCD1 mediates the plasma lipid response to LXR agonist treatment in Ldlr-/-
mice. Treatment of mice with a synthetic LXR agonist, T0901317, has been shown to be antiatherogenic in hyperlipidemic LDLR-deficient mice (36, 37), but its therapeutic utility has been limited by the accompanying severe HTG (36, 37) and hepatic steatosis (68, 69) . controls, a similar relative reduction to that induced by SCD1 deficiency in hyperlipidemic mice prior to treatment with an LXR agonist. Plasma TC was ~ 10-30% lower at all time-points in SCD1-deficient mice compared with controls, primarily due to a reduction in non-HDL cholesterol (Fig. 8b) . (Fig. 8c) . To explore the molecular mechanism by which SCD1 influences plasma lipids in T0901317-treated hyperlipidemic mice, we assessed hepatic expression levels of various genes (Fig. 8d) . We observed a 77% reduction in the level of FAS mRNA in SCD1-deficient mice (p = 0.0020). A reduction of FAS indicates that endogenous fatty acids are likely produced at a reduced rate and are less available for generation of triglycerides for secretion into the plasma. Trends toward decreases in transcripts of other lipogenic genes (acetyl-CoA synthetase, 78% reduction, p = 0.22; glycerol-3-phosphate acyltransferase, 51% reduction, p = 0.14) with SCD1 deficiency were also detected in mice fed the LXR agonist.
Hepatic ABCA1 protein expression was increased by 45% in T0901317-treated (Fig. 8e , p = 0.002), which at least partly might explain the increased HDL levels (70, 71) . However, we did not observe a significant alteration in the level of Abca1 mRNA (Fig. 8d) , suggesting that the increased ABCA1 protein level is not due to increased synthesis of ABCA1, but rather due to alterations in post-transcriptional regulation.
Discussion
We have shown that an absence of SCD1 improves the metabolic phenotype of a mouse model of FH on a western diet. Absence of the Scd1 gene product reduces hepatic and plasma TG, and strongly inhibits diet-induced weight gain in LDLR-deficient mice.
Absence of SCD1 also provides striking protection from diet-induced insulin resistance as measured by intraperitoneal glucose and insulin tolerance testing. Normolipidemic SCD1-deficient mice are known to be protected from insulin resistance and diet-induced obesity (34) . The role of SCD1 in resistance to obesity has also been expanded to include the leptin-deficient model of obesity (35) . We have now extended the findings and demonstrate that the absence of SCD1 provides significant protection from diet-induced obesity in the hyperlipidemic LDLR-deficient model. Liver TG are reduced by 40-65% in SCD1-deficient mice (6, 54) and TG synthesis is also reduced (35, 54, 72) . The most profound impact of absence of SCD1 on the metabolic features of LDLR-deficient mice in this study was a 5-fold reduction in hepatic steatosis, a greater relative reduction than the reductions of ~65% observed previously in chow-fed SCD1-deficient genetic models of obesity (35) and lipodystrophy (58) .
Fatty liver is frequently observed in individuals with obesity, type 2 diabetes, and hyperlipidemia. Moreover, the degree of steatosis in non-alcoholic fatty liver disease is proportional to the degree of obesity (73) , and insulin resistance is almost universally observed in non-alcoholic fatty liver disease (74, 75) . Short term high-fat feeding in rodents in the absence of increases in peripheral fat accumulation has previously demonstrated a causal role for intracellular hepatic fat accumulation in the pathogenesis of hepatic insulin resistance (76) . Furthermore, hepatic fat accumulation is often accompanied by a chronic, subacute state of inflammation, which can increase insulin resistance (77, 78) .
Thus the dramatic reduction in hepatic triglycerides that we observe in the absence of SCD1 may contribute in part to increasing insulin sensitivity. However, increased levels of saturated fatty acids (79, 80) and overexpression of SCD1 (81) decrease insulin signaling in 12 muscle cells, suggesting that absence of SCD1 may also contribute to increased insulin sensitivity in skeletal muscle in addition to the liver.
The role of SCD1 in regulating plasma TG has been evaluated in several studies and a reduction in plasma TG has not been consistently observed. Some studies have shown plasma TG reduced by over 50% (6, 55, 82) , but two studies have shown no significant differences (56, 57). It is not known whether the phenotypic differences could be attributed to the variations in age, sex, diet, fasting protocol, or genetic background of mice in the different studies. SCD1 deficient mice have a markedly reduced rate of VLDL-TG production (35) , and the effect on plasma TG levels may be more apparent in hyperlipidemic mice. Our results show that absence of SCD1 reduces plasma lipids (TC, TG) and improves lipoprotein profiles in LDLR-deficient mice.
A potential mechanism for the reduction in hepatic and plasma lipids in SCD1-deficient mice is reduced lipogenesis. We found that SCD1 deficiency markedly reduces fatty acid synthesis in hepatocytes and reduces hepatic mRNA levels of the two SREBP-1c regulated genes that encode enzymes required for long-chain fatty acid synthesis, ACC-1 and FAS. These data are consistent with previous studies that demonstrated reduced ACC-1 and FAS hepatic expression levels (34, 58, 83, 84) and reduced ACC activity (84) in SCD1-deficient chow-fed mice, and indicate that a reduction in hepatic de novo fatty acid synthesis is likely to be a major contributor to the decreased hepatic and plasma lipids we observe in hyperlipidemic SCD1-deficient mice.
T0901317 is a synthetic LXR agonist which has been shown to be atheroprotective in hyperlipidemic mice (36, 37), an effect that is postulated to be mediated by stimulating cholesterol efflux in macrophages (36, 37, 69). However, LXR activation has been by guest, on September 21, 2017 www.jlr.org Downloaded from 13 observed to lead to undesirable side effects, specifically HTG (36, 37) and hepatic steatosis.
Our data demonstrate that absence of SCD1 significantly influences the plasma lipid response to antiatherogenic LXR agonist treatment, reducing non-HDL cholesterol and increasing beneficial HDL cholesterol. In addition, SCD1 deficiency is also able to partially improve LXR-induced HTG in the hyperlipidemic LDLR-deficient model. These data are consistent with data in a recent study of chow-fed mice that have shown that SCD1 can regulate the metabolic response to a synthetic LXR agonist (26) Increased levels of SCD1 and its MUFA products inhibit cholesterol efflux mediated by ABCA1 (85-87) by a mechanism that may involve increased turnover rather than altered transcript levels (88) . In addition, SCD1 deficiency can increase hepatic ABCA1 in SCD1-deficient mice fed a very-low fat diet (89) . Our data now provide evidence that the increased plasma HDL cholesterol observed in hyperlipidemic LXR-treated mice is accompanied by increased levels of the ABCA1 protein but no significant alteration in the level of Abca1 mRNA, consistent with a mechanism involving alterations in posttranscriptional regulation.
In summary, our results establish the robust impact of SCD1 deficiency on the metabolic phenotype of the hyperlipidemic LDLR-deficient mouse model, including reduced hepatic and plasma TG, reduced diet-induced weight gain and insulin resistance, and a partially reduced hypertriglyceridemic response to an LXR agonist. determination of apoB and apoE as described (90) . Briefly, 10 µg of protein was added to each lane of the gel. Gels were stained with Coomassie blue and bands corresponding to apoB and apoE were quantified by scanning using a densitometer. Unfractionated plasma levels apoC-III were determined by immunonephelometry with the use of mouse-specific antibodies developed in rabbits. The distribution of lipids in plasma lipoproteins was assessed as described (91) .
Methods
Animals and diet. Mice carrying the
Hepatocyte isolation and radiolabeling with [ 3 H]acetate. Primary hepatocytes were isolated as described (92). Briefly, mice fed a western diet for four weeks were anesthetized by intraperitoneal injection of Somnotol (22 µl/50 g body weight) and the livers were perfused with Hanks' EGTA solution containing 1 mg/ml insulin followed by Insulin tolerance tests were performed on 12-hour fasted mice injected with 0.75 U/kg human recombinant insulin (Novo Nordisk, Princeton, NJ). We measured plasma insulin by ELISA (Crystal Chem, Downers Grove, IL).
Real-time PCR and immunoblotting.
We extracted total RNA from liver using the TRIzol reagent according to manufacturer's instructions (Invitrogen Canada, Burlington, ON, CA).
1 microgram of DNase-treated RNA was reverse-transcribed using Superscript II (Invitrogen Canada, Burlington, ON, Canada) to generate RNAse H-treated cDNA for realtime PCR using SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA) in an ABI Prism 7700 Sequence Detection System. We used Gapdh as the invariant control. mRNA levels in control mice were arbitrarily set at 1.
Western blotting was performed as previously described (93) . Briefly, tissues were homogenized in low salt lysis buffer containing complete protease inhibitor (Roche Diagnostics, Laval, QC), and protein concentration was determined by the Lowry assay Cholesterol, mg/dL 2192 ± 635 (11) 1614 ± 307 (8) by guest, on September 21, 2017 
